Abstract
Introduction Under vaccination amongst underserved groups remains low due to existing disparities. This is particularly the case with post-pandemic COVID-19 vaccinations, and other vaccine-preventable diseases including measles, Mumps and Rubella (MMR) or influenza. Therefore, we aim to 1) to determine the feasibility and practicality of implementing a patient engagement tool (PET) and gain vital insights to plan a subsequent definitive randomised controlled trial (RCT) to evaluate the effectiveness of this tool for increasing uptake of COVID-19 and Flu vaccination; 2) and to define the appropriate level of support needed for health care providers at site-level to ensure successful implementation of the PET and to identify supporting activities needed to implement interventions for COVID-19 and Flu vaccinations.
Methods and Analysis This is a randomised controlled feasibility study evaluating a co-designed PET, involving randomisation at individual and cluster level. For individual randomisation, patients will be individually randomised 1:1 to receive the intervention (PET) or routine care; whereas for cluster randomisation six GP practices will be randomised 1:1, and divided into two tranches at two separate time points. Both groups will receive training and activation of the software. Data will be analysed using statistical software R (4.0 or greater) or STATA (17 or greater). Baseline characteristics will be summarised and presented in groups based on an intention to treat (ITT) basis with categorical data; including demographics, socioeconomic variables, co-morbidities, and vaccination status.
Ethics and Dissemination Ethical approval was granted Westminster Ethics Committee (ref: 316860). Our dissemination strategy targets three audiences: (1) Policy makers, public and health service managers and clinicians responsible for delivering vaccines and infection prevention services; (2) patients and public from underserved population groups (3) academics.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05866237
Funding Statement
This study has been funded by Barts Charity
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Westminster Ethics Committee (ref: 316860)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Trial registration Number: ClinicalTrials.gov (Trial ID: NCT05866237)
Data Availability
Data is not yet available as this is a study protocol for a future study